Mansour Ziad, Kochetkova Evgenia A, Ducrocq Xavier, Vasilescu Mircea-Dan, Maxant Guillaume, Buggenhout Alexis, Wihlm Jean-Marie, Massard Gilbert
Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, 67091 Strasbourg, France.
Eur J Cardiothorac Surg. 2007 Feb;31(2):181-5. doi: 10.1016/j.ejcts.2006.11.008. Epub 2006 Dec 1.
There is an ongoing debate whether induction therapy increases post-operative mortality and morbidity, especially when performing pneumonectomy. We therefore reviewed a consecutive series of patients having undergone pneumonectomy in a single center.
The charts of 298 patients operated on between January 1999 and July 2005 were reviewed. Patients were divided into two groups: group 1 included those who received induction chemotherapy (60 patients, 20.1%), and group 2 included those who underwent surgery alone (238 patients, 79.9%). Endpoints were operative mortality at 30 and at 90 days, and major complications such as empyema, bronchial fistula and acute respiratory distress syndrome. Statistical analyses were performed using SPSS 11.0 software.
Demographic data were similar for both groups when considering side of operation, comorbidity and weaning from tobacco; patients were older in group 2 (61.83+/-9.58 years vs 57.75+/-8.94 years; p=0.003) and there were more female patients in group 2 (17.2% vs 5.0%; p=0.010). Post-operative mortality at 30 days was 6.7% in group 1 and 5.5% in group 2 (p=0.458), and 11.7% for group 1 and 10.9% in group 2 at 90 days (p=0.512). Incidence of empyema was 1.7% in group 1 and 2.1% in group 2 (p=0.652); incidence of bronchopleural fistulas was 1.7% in group 1 and 5.5% in group 2 (p=0.188); incidence of acute respiratory distress syndrome was 3.3% in group 1 and 3.4% in group 2 (p=0.675).
In opposition to previous reports, induction chemotherapy did not significantly jeopardize post-operative outcome following pneumonectomy in our experience.
关于诱导治疗是否会增加术后死亡率和发病率,尤其是在进行肺切除术时,目前仍存在争议。因此,我们回顾了在单一中心连续接受肺切除术的一系列患者。
回顾了1999年1月至2005年7月期间接受手术的298例患者的病历。患者分为两组:第1组包括接受诱导化疗的患者(60例,20.1%),第2组包括仅接受手术的患者(238例,79.9%)。观察终点为30天和90天的手术死亡率,以及主要并发症,如脓胸、支气管瘘和急性呼吸窘迫综合征。使用SPSS 11.0软件进行统计分析。
在考虑手术侧、合并症和戒烟情况时,两组的人口统计学数据相似;第2组患者年龄较大(61.83±9.58岁对57.75±8.94岁;p = 0.003),第2组女性患者更多(17.2%对5.0%;p = 0.010)。第1组30天术后死亡率为6.7%,第2组为5.5%(p = 0.458),第1组90天为11.7%,第2组为10.9%(p = 0.512)。脓胸发生率第1组为1.7%,第2组为2.1%(p = 0.652);支气管胸膜瘘发生率第1组为1.7%,第2组为5.5%(p = 0.188);急性呼吸窘迫综合征发生率第1组为3.3%,第2组为3.4%(p = 0.675)。
与之前的报道相反,根据我们的经验,诱导化疗在肺切除术后并未显著影响手术结果。